Skip to the page

Data / Drug companies / Eli Lilly and Company

Eli Lilly and Company: 183 products in the FDA NDC directory, labeler code 0002

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Eli Lilly and Company (labeler code 0002) lists 183 products in the FDA National Drug Code Directory, covering 30 finished drugs by generic name. By type: 141 prescription drugs, 31 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 23, 2026.

The request: Watch Eli Lilly and Company (FDA labeler code 0002): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0002
Products in commercial distribution
183
Packages
226
Finished drugs by generic name
30
Prescription products
141
Over the counter products
6
Controlled substance products
Schedule V 2
Flagged as original packager
127 of 127 products that carry the flag
Started marketing in the last 12 months
32
Products with a marketing end date set
17
Earliest marketing start
October 28, 1982
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)8948.6%
Biologics (BLA)5731.1%
Drugs for further processing3116.9%
Bulk ingredients52.7%
Emergency use authorization10.5%

Products by type

TypeProductsShare
Prescription drugs14177%
Drugs for further processing3116.9%
Over the counter drugs63.3%
Bulk ingredients52.7%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Tirzepatide482
Insulin lispro134
Insulin human74
Mirikizumab-mrkz71
Atomoxetine hydrochloride78
Orforglipron61
Selpercatinib61
Insulin lispro-aabc62
Ixekizumab41
Baricitinib41
Abemaciclib41
Dulaglutide42
Galcanezumab-gnlm31
Tadalafil354
Somatropin36
Pirtobrutinib21
Teriparatide27
Ramucirumab21
Insulin efsitora alfa-gobe21
Lebrikizumab-lbkz21
Pemetrexed disodium214
Lasmiditan21
Donanemab-azbt11
Raloxifene hydrochloride116
Diluent11
Flortaucipir f-1811
Imlunestrant11
Insulin glargine-aglr12
Florbetapir f 1811
Insulin glargine15

Dosage forms

Dosage formProductsShare
Injection, solution11663.4%
Injection, suspension158.2%
Tablet, film coated147.7%
Capsule94.9%
Tablet73.8%
Tablet, coated63.3%
Kit52.7%
Solution42.2%
Crystal42.2%
Injection, powder, lyophilized, for solution21.1%
Powder10.5%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
ONSWIK KwikPen0002-5240Injection, solutionBiologics (BLA)September 23, 2026
ONSWIK KwikPen0002-5137Injection, solutionBiologics (BLA)September 23, 2026
Foundayo0002-4953Tablet, film coatedNew drug applications (NDA)April 1, 2026
Foundayo0002-4839Tablet, film coatedNew drug applications (NDA)April 1, 2026
Foundayo0002-4803Tablet, film coatedNew drug applications (NDA)April 1, 2026
Foundayo0002-4794Tablet, film coatedNew drug applications (NDA)April 1, 2026
Foundayo0002-4503Tablet, film coatedNew drug applications (NDA)April 1, 2026
Foundayo0002-4178Tablet, film coatedNew drug applications (NDA)April 1, 2026
Zepbound KwikPen0002-3566Injection, solutionNew drug applications (NDA)January 20, 2026
Zepbound KwikPen0002-3555Injection, solutionNew drug applications (NDA)January 20, 2026
Zepbound KwikPen0002-3544Injection, solutionNew drug applications (NDA)January 20, 2026
Zepbound KwikPen0002-3533Injection, solutionNew drug applications (NDA)January 20, 2026
Zepbound KwikPen0002-3522Injection, solutionNew drug applications (NDA)January 20, 2026
Zepbound KwikPen0002-3511Injection, solutionNew drug applications (NDA)January 20, 2026
Mounjaro KwikPen0002-3466Injection, solutionNew drug applications (NDA)January 20, 2026
Mounjaro KwikPen0002-3455Injection, solutionNew drug applications (NDA)January 20, 2026
Mounjaro KwikPen0002-3444Injection, solutionNew drug applications (NDA)January 20, 2026
Mounjaro KwikPen0002-3433Injection, solutionNew drug applications (NDA)January 20, 2026
Mounjaro KwikPen0002-3422Injection, solutionNew drug applications (NDA)January 20, 2026
Mounjaro KwikPen0002-3411Injection, solutionNew drug applications (NDA)January 20, 2026
Zepbound0002-6612Injection, solutionNew drug applications (NDA)January 7, 2026
Zepbound0002-6523Injection, solutionNew drug applications (NDA)January 7, 2026
Zepbound0002-6304Injection, solutionNew drug applications (NDA)January 7, 2026
Zepbound0002-6210Injection, solutionNew drug applications (NDA)January 7, 2026
Zepbound0002-6103Injection, solutionNew drug applications (NDA)January 7, 2026

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.